Literature DB >> 26442610

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.

M Cavo1, L Pantani1, A Pezzi1, M T Petrucci2, F Patriarca3, F Di Raimondo4, G Marzocchi1, M Galli5, V Montefusco6, E Zamagni1, B Gamberi7, P Tacchetti1, A Brioli1, A Palumbo8, P Sonneveld9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26442610     DOI： 10.1038/leu.2015.274

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.

Authors:  Paola Tacchetti; Carolina Terragna; Monica Galli; Elena Zamagni; Maria Teresa Petrucci; Annalisa Pezzi; Vittorio Montefusco; Marina Martello; Patrizia Tosi; Luca Baldini; Jacopo Peccatori; Miriana Ruggieri; Lucia Pantani; Antonio Lazzaro; Francesca Elice; Serena Rocchi; Alessandro Gozzetti; Guido Cavaletti; Antonio Palumbo; Michele Cavo
Journal:  Am J Hematol       Date:  2014-09-17       Impact factor: 10.047

2.  Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

Authors:  Shaji Kumar; Ian Flinn; Paul G Richardson; Parameswaran Hari; Natalie Callander; Stephen J Noga; A Keith Stewart; Francesco Turturro; Robert Rifkin; Jeffrey Wolf; Jose Estevam; George Mulligan; Hongliang Shi; Iain J Webb; S Vincent Rajkumar
Journal:  Blood       Date:  2012-03-15       Impact factor: 22.113

3.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Authors:  Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

4.  Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Authors:  E K Mai; U Bertsch; J Dürig; C Kunz; M Haenel; I W Blau; M Munder; A Jauch; B Schurich; T Hielscher; M Merz; B Huegle-Doerr; A Seckinger; D Hose; J Hillengass; M S Raab; K Neben; H-W Lindemann; M Zeis; C Gerecke; I G H Schmidt-Wolf; K Weisel; C Scheid; H Salwender; H Goldschmidt
Journal:  Leukemia       Date:  2015-03-19       Impact factor: 11.528

5.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Authors:  Michele Cavo; S Vincent Rajkumar; Antonio Palumbo; Philippe Moreau; Robert Orlowski; Joan Bladé; Orhan Sezer; Heinz Ludwig; Meletios A Dimopoulos; Michel Attal; Pieter Sonneveld; Mario Boccadoro; Kenneth C Anderson; Paul G Richardson; William Bensinger; Hans E Johnsen; Nicolaus Kroeger; Gösta Gahrton; P Leif Bergsagel; David H Vesole; Hermann Einsele; Sundar Jagannath; Ruben Niesvizky; Brian G M Durie; Jesus San Miguel; Sagar Lonial
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

6.  Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Authors:  Michele Cavo; Paola Tacchetti; Francesca Patriarca; Maria Teresa Petrucci; Lucia Pantani; Monica Galli; Francesco Di Raimondo; Claudia Crippa; Elena Zamagni; Antonio Palumbo; Massimo Offidani; Paolo Corradini; Franco Narni; Antonio Spadano; Norbert Pescosta; Giorgio Lambertenghi Deliliers; Antonio Ledda; Claudia Cellini; Tommaso Caravita; Patrizia Tosi; Michele Baccarani
Journal:  Lancet       Date:  2010-12-09       Impact factor: 79.321

7.  Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Authors:  Philippe Moreau; Herve Avet-Loiseau; Thierry Facon; Michel Attal; Mourad Tiab; Cyrille Hulin; Chantal Doyen; Laurent Garderet; Edouard Randriamalala; Carla Araujo; Gérard Lepeu; Gerald Marit; Denis Caillot; Martine Escoffre; Bruno Lioure; Lotfi Benboubker; Brigitte Pégourié; Brigitte Kolb; Anne Marie Stoppa; Jean-Gabriel Fuzibet; Olivier Decaux; Mamoun Dib; Christian Berthou; Carine Chaleteix; Catherine Sebban; Catherine Traullé; Jean Fontan; Marc Wetterwald; Pascal Lenain; Claire Mathiot; Jean-Luc Harousseau
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

Review 8.  The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.

Authors:  Annamaria Brioli; Lorenzo Melchor; Michele Cavo; Gareth J Morgan
Journal:  Br J Haematol       Date:  2014-03-02       Impact factor: 6.998

9.  Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Authors:  Laura Rosiñol; Albert Oriol; Ana Isabel Teruel; Dolores Hernández; Javier López-Jiménez; Javier de la Rubia; Miquel Granell; Joan Besalduch; Luis Palomera; Yolanda González; María Asunción Etxebeste; Joaquín Díaz-Mediavilla; Miguel T Hernández; Felipe de Arriba; Norma C Gutiérrez; María Luisa Martín-Ramos; María Teresa Cibeira; María Victoria Mateos; Joaquín Martínez; Adrián Alegre; Juan José Lahuerta; Jesús San Miguel; Joan Bladé
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113

Review 10.  Association of response endpoints with survival outcomes in multiple myeloma.

Authors:  S Lonial; K C Anderson
Journal:  Leukemia       Date:  2013-07-19       Impact factor: 11.528
View more
  16 in total

1.  Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

Authors:  M Sobh; M Michallet; G Gahrton; S Iacobelli; A van Biezen; S Schönland; E Petersen; N Schaap; F Bonifazi; L Volin; E Meijer; D Niederwieser; J El Cheikh; R Tabrizi; N Fegeux; J Finke; D Bunjes; J Cornelissen; H Einsele; B Bruno; M Potter; R Fanin; M Mohty; L Garderet; N Kröger
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528

2.  Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.

Authors:  Laura Rosiñol; Albert Oriol; Rafael Rios; Anna Sureda; María Jesús Blanchard; Miguel Teodoro Hernández; Rafael Martínez-Martínez; Jose M Moraleda; Isidro Jarque; Juan Bargay; Mercedes Gironella; Felipe de Arriba; Luis Palomera; Yolanda González-Montes; Josep M Martí; Isabel Krsnik; Jose M Arguiñano; Maria Esther González; Ana Pilar González; Luis Felipe Casado; Lucia López-Anglada; Bruno Paiva; Maria-Victoria Mateos; Jesus F San Miguel; Juan-José Lahuerta; Joan Bladé
Journal:  Blood       Date:  2019-10-17       Impact factor: 22.113

3.  Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis.

Authors:  F Gay; S Oliva; M T Petrucci; V Montefusco; C Conticello; P Musto; L Catalano; A Evangelista; S Spada; P Campbell; R Ria; M Salvini; M Offidani; A M Carella; P Omedé; A M Liberati; R Troia; A M Cafro; A Malfitano; A P Falcone; T Caravita; F Patriarca; A Nagler; A Spencer; R Hajek; A Palumbo; M Boccadoro
Journal:  Leukemia       Date:  2016-12-23       Impact factor: 11.528

4.  Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.

Authors:  Efstathios Kastritis; Ioanna Dialoupi; Maria Gavriatopoulou; Maria Roussou; Nikolaos Kanellias; Despina Fotiou; Ioannis Ntanasis-Stathopoulos; Elektra Papadopoulou; Dimitrios C Ziogas; Kimon Stamatelopoulos; Efstathios Manios; Argyrios Ntalianis; Evangelos Eleutherakis-Papaiakovou; Asimina Papanikolaou; Magdalini Migkou; Aristea-Maria Papanota; Harikleia Gakiopoulou; Erasmia Psimenou; Maria Irini Tselegkidi; Ourania Tsitsilonis; Ioannis Kostopoulos; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Blood Adv       Date:  2019-10-22

5.  Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

Authors:  Edward A Stadtmauer; Marcelo C Pasquini; Beth Blackwell; Parameswaran Hari; Asad Bashey; Steven Devine; Yvonne Efebera; Siddharta Ganguly; Cristina Gasparetto; Nancy Geller; Mary M Horowitz; John Koreth; Kristin Knust; Heather Landau; Claudio Brunstein; Philip McCarthy; Courtney Nelson; Muzaffar H Qazilbash; Nina Shah; David H Vesole; Ravi Vij; Dan T Vogl; Sergio Giralt; George Somlo; Amrita Krishnan
Journal:  J Clin Oncol       Date:  2019-01-17       Impact factor: 44.544

6.  Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.

Authors:  Graham H Jackson; Faith E Davies; Charlotte Pawlyn; David A Cairns; Alina Striha; Corinne Collett; Anna Waterhouse; John R Jones; Bhuvan Kishore; Mamta Garg; Cathy D Williams; Kamaraj Karunanithi; Jindriska Lindsay; David Allotey; Salim Shafeek; Matthew W Jenner; Gordon Cook; Nigel H Russell; Martin F Kaiser; Mark T Drayson; Roger G Owen; Walter M Gregory; Gareth J Morgan; Uk Ncri Haematological Oncology Clinical Studies Group
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

Review 7.  Frontline therapy for newly diagnosed patients with multiple myeloma.

Authors:  Sung-Hoon Jung; Jae-Cheol Jo; Ga-Young Song; Seo-Yeon Ahn; Deok-Hwan Yang; Jae-Sook Ahn; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Blood Res       Date:  2020-07-31

8.  [Efficacy and safety of CTD and PCD regimens in treatment of patients with newly diagnosed multiple myeloma].

Authors:  Y Gu; Y H Yuan; Q L Shi; X Y Qu; J Xu; R Guo; J D Xu; J Y Li; L J Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-04-14

9.  Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan.

Authors:  Yu-Chin Hung; Jyh-Pyng Gau; Shang-Yi Huang; Bor-Sheng Ko; Chieh-Lin Jerry Teng
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

10.  Identification of patients at high risk of secondary extramedullary multiple myeloma development.

Authors:  Martin Stork; Sabina Sevcikova; Jiri Minarik; Petra Krhovska; Jakub Radocha; Lenka Pospisilova; Lucie Brozova; Jiri Jarkovsky; Ivan Spicka; Jan Straub; Petr Pavlicek; Alexandra Jungova; Tomas Jelinek; Viera Sandecka; Vladimir Maisnar; Roman Hajek; Ludek Pour
Journal:  Br J Haematol       Date:  2021-11-02       Impact factor: 8.615
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.